Using an Atrial Fibrillation Decision Support Tool for Thromboprophylaxis in Atrial Fibrillation: Effect of Sex and Age

Journal of the American Geriatrics Society

Volumn 64, Issue 5, 2016, Pages 1054-1060

  Eckman, Mark H ^a,b   Lip, Gregory Y H ^c   Wise, Ruth E ^a,b   Speer, Barbara ^a   Sullivan, Megan ^d   Walker, Nita ^a,b   Kissela, Brett ^a   Flaherty, Matthew L ^a   Kleindorfer, Dawn ^a   Baker, Peter ^b   Ireton, Robert ^b   Hoskins, Dave ^b   Harnett, Brett M ^b   Aguilar, Carlos ^b   Leonard, Anthony ^a   Arduser, Lora ^b   Steen, Dylan ^b   Costea, Alexandru ^b   Kues, John ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF CINCINNATI   (United States)

^c UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^d UNIVERSITY OF CINCINNATI ACADEMIC HEALTH CENTER   (United States)

Author keywords

anticoagulation; aspirin; atrial fibrillation; elderly; novel oral anticoagulants; sex differences; warfarin

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; APIXABAN; CLOPIDOGREL; DABIGATRAN; PRASUGREL; RIVAROXABAN; WARFARIN;

ADULT; AGE; AGED; ANTICOAGULANT THERAPY; ARTICLE; ATRIAL FIBRILLATION; CEREBROVASCULAR ACCIDENT; CHEMOPROPHYLAXIS; COHORT ANALYSIS; DECISION SUPPORT SYSTEM; FEMALE; GENDER; HUMAN; MAJOR CLINICAL STUDY; MALE; QUALITY ADJUSTED LIFE YEAR; RETROSPECTIVE STUDY;

EID: 84990198421     PISSN: 00028614     EISSN: 15325415     Source Type: Journal    
DOI: 10.1111/jgs.14099     Document Type: Article

References (45)

1. Go AS, Hylek EM, Phillips KA et al. Prevalence of diagnosed atrial fibrillation in adults: National implications for rhythm management and stroke prevention: The AnTicoagulation and Risk Factors In Atrial Fibrillation (ATRIA) Study. JAMA 2001;285:2370–2375.
2. Wolf PA, D'Agostino RB, Belanger AJ et al. Probability of stroke: A risk profile from the Framingham Study. Stroke 1991;22:312–318.
3. Beyth RJ, Antani MR, Covinsky KE et al. Why isn't warfarin prescribed to patients with nonrheumatic atrial fibrillation? J Gen Intern Med 1996;11:721–728.
4. Gage BF, Boechler M, Doggette AL et al. Adverse outcomes and predictors of underuse of antithrombotic therapy in Medicare beneficiaries with chronic atrial fibrillation. Stroke 2000;31:822–827.
5. Humphries KH, Kerr CR, Connolly SJ et al. New-onset atrial fibrillation: Sex differences in presentation, treatment, and outcome. Circulation 2001;103:2365–2370.
6. Ogilvie IM, Newton N, Welner SA et al. Underuse of oral anticoagulants in atrial fibrillation: A systematic review. Am J Med 2010;123:e4.
7. Ewen E, Zhang Z, Simon TA et al. Patterns of warfarin use and subsequent outcomes in atrial fibrillation in primary care practices. Vasc Health Risk Manag 2012;8:587–598.
8. Conen D, Chae CU, Glynn RJ et al. Risk of death and cardiovascular events in initially healthy women with new-onset atrial fibrillation. JAMA 2011;305:2080–2087.
9. Bates SM, Greer IA, Hirsh J et al. Use of antithrombotic agents during pregnancy: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126:627S–644S.
10. Frost L, Johnsen SP, Pedersen L et al. Atrial fibrillation or flutter and stroke: A Danish population-based study of the effectiveness of oral anticoagulation in clinical practice. J Intern Med 2002;252:64–69.
11. Go AS, Hylek EM, Borowsky LH et al. Warfarin use among ambulatory patients with nonvalvular atrial fibrillation: The AnTicoagulation and Risk factors In Atrial fibrillation (ATRIA) study. Ann Intern Med 1999;131:927–934.
12. Sudlow M, Thomson R, Thwaites B et al. Prevalence of atrial fibrillation and eligibility for anticoagulants in the community. Lancet 1998;352:1167–1171.
13. Fang MC, Singer DE, Chang Y et al. Gender differences in the risk of ischemic stroke and peripheral embolism in atrial fibrillation: The AnTicoagulation and Risk factors In Atrial fibrillation (ATRIA) study. Circulation 2005;112:1687–1691.
14. McCrory DC, Matchar DB, Samsa G et al. Physician attitudes about anticoagulation for nonvalvular atrial fibrillation in the elderly. Arch Intern Med 1995;155:277–281.
15. Fang MC, Stafford RS, Ruskin JN et al. National trends in antiarrhythmic and antithrombotic medication use in atrial fibrillation. Arch Intern Med 2004;164:55–60.
16. McCormick D, Gurwitz JH, Goldberg RJ et al. Prevalence and quality of warfarin use for patients with atrial fibrillation in the long-term care setting. Arch Intern Med 2001;161:2458–2463.
17. Bungard TJ, Ghali WA, McAlister FA et al. Physicians' perceptions of the benefits and risks of warfarin for patients with nonvalvular atrial fibrillation. Can Med Assoc J 2001;165:301–302.
18. Bungard TJ, Ghali WA, Teo KK et al. Why do patients with atrial fibrillation not receive warfarin? Arch Intern Med 2000;160:41–46.
19. Monette J, Gurwitz JH, Rochon PA et al. Physician attitudes concerning warfarin for stroke prevention in atrial fibrillation: Results of a survey of long-term care practitioners. J Am Geriatr Soc 1997;45:1060–1065.
20. Deedwania PC. New oral anticoagulants in elderly patients with atrial fibrillation. Am J Med 2013;126:289–296.
21. Harper P, Young L, Merriman E. Bleeding risk with dabigatran in the frail elderly. N Engl J Med 2012;366:864–866.
22. Legrand M, Mateo J, Aribaud A et al. The use of dabigatran in elderly patients. Arch Intern Med 2011;171:1285–1286.
23. Wychowski MK, Kouides PA. Dabigatran-induced gastrointestinal bleeding in an elderly patient with moderate renal impairment. Ann Pharmacother 2012;46:e10.
24. Sardar P, Chatterjee S, Chaudhari S et al. New oral anticoagulants in elderly adults: Evidence from a meta-analysis of randomized trials. J Am Geriatr Soc 2014;62:857–864.
25. January CT, Wann LS, Alpert JS et al. AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. Circulation 2014;130:e199–e267.
26. Olesen JB, Lip GY, Hansen ML et al. Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: Nationwide cohort study. BMJ 2011;342:d124.
27. Friberg L, Rosenqvist M, Lip GY. Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: The Swedish Atrial Fibrillation cohort study. Eur Heart J 2012;33:1500–1510.
28. Eckman MH, Wise RE, Speer B et al. Integrating real-time clinical information to provide estimates of net clinical benefit of antithrombotic therapy for patients with atrial fibrillation. Circ Cardiovasc Qual Outcomes 2014;7:680–686.
29. Eckman MH, Singer DE, Rosand J et al. Moving the tipping point: The decision to anticoagulate patients with atrial fibrillation. Circ Cardiovasc Qual Outcomes 2011;4:14–21.
30. Camm AJ, Lip GY, De Caterina R et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: An update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 2012;33:2719–2747.
31. Fang MC, Go AS, Hylek EM et al. Age and the risk of warfarin-associated hemorrhage: The AnTicoagulation and Risk factors In Atrial fibrillation study. J Am Geriatr Soc 2006;54:1231–1236.
32. Quilliam BJ, Lapane KL. Clinical correlates and drug treatment of residents with stroke in long-term care. Stroke 2001;32:1385–1393.
33. Friberg L, Hammar N, Ringh M et al. Stroke prophylaxis in atrial fibrillation: Who gets it and who does not? Report from the Stockholm Cohort-study on Atrial Fibrillation (SCAF-study). Eur Heart J 2006;27:1954–1964.
34. Hylek EM, D'Antonio J, Evans-Molina C et al. Translating the results of randomized trials into clinical practice: The challenge of warfarin candidacy among hospitalized elderly patients with atrial fibrillation. Stroke 2006;37:1075–1080.
35. Gallagher AM, Rietbrock S, Plumb J et al. Initiation and persistence of warfarin or aspirin in patients with chronic atrial fibrillation in general practice: Do the appropriate patients receive stroke prophylaxis? J Thromb Haemost 2008;6:1500–1506.
36. Perez I, Melbourn A, Kalra L. Use of antithrombotic measures for stroke prevention in atrial fibrillation. Heart 1999;82:570–574.
37. van Walraven C, Hart RG, Connolly S et al. Effect of age on stroke prevention therapy in patients with atrial fibrillation: The atrial fibrillation investigators. Stroke 2009;40:1410–1416.
38. Mant J, Hobbs FD, Fletcher K et al. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): A randomised controlled trial. Lancet 2007;370:493–503.
39. Garcia D, Hylek E. Stroke prevention in elderly patients with atrial fibrillation. Lancet 2007;370:460–461.
40. Flaker G, Ezekowitz M, Yusuf S et al. Efficacy and safety of dabigatran compared to warfarin in patients with paroxysmal, persistent, and permanent atrial fibrillation: Results from the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) study. J Am Coll Cardiol 2012;59:854–855.
41. Halperin JL, Hankey GJ, Wojdyla DM et al. Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF). Circulation 2014;130:138–146.
42. Avezum A, Lopes RD, Schulte PJ et al. Apixaban compared with warfarin in patients with atrial fibrillation and valvular heart disease: Findings from the ARISTOTLE Trial. Circulation 2015;132:624–632.
43. Johnson SA, Rondina MT. Edoxaban was noninferior to warfarin for preventing stroke or systemic embolism in atrial fibrillation. Ann Intern Med 2014;160:JC7.
44. Miller CS, Grandi SM, Shimony A et al. Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation. Am J Cardiol 2012;110:453–460.
45. Barco S, Cheung YW, Eikelboom JW et al. New oral anticoagulants in elderly patients. Best Pract Res Clin Haematol 2013;26:215–224.